Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the corporate introduced updates relating to its pipeline growth applications and present money place. The outstanding inventory worth rally underscores constructive traders’ expectations relating to the pipeline potential of the clinical-stage, oncology-focused biotech firm.
CMPX’s Lead Pipeline Program
Compass Therapeutics’ lead therapeutic candidate, tovecimig (CTX-009), is at the moment being evaluated in a part II/III examine together with paclitaxel in sufferers with superior biliary tract most cancers (BTC), who obtained one prior systemic chemotherapy routine. The mid to late-stage examine is designed to evaluate the security and efficacy of the mixture of tovecimig and paclitaxel versus paclitaxel alone in sufferers handled in second-line settings.
Prior to now three months, CMPX’s shares have surged 77.6% in opposition to the industry’s 7.1% decline.
Picture Supply: Zacks Funding Analysis
Compass Therapeutics is on observe to report top-line information in the US towards the tip of the primary quarter of 2025. Please notice that the tovecimig/paclitaxel combo enjoys the FDA’s Quick Observe designation in the US to deal with the BTC indication.
Moreover, Compass Therapeutics can also be planning to provoke a separate part II examine of tovecimig, together with chemotherapy in mid-2025 to deal with sufferers with DLL4-positive colorectal most cancers within the second-line setting.
An investigator-sponsored examine of tovecimig for first-line BTC remedy at MD Anderson Most cancers Heart is about to start in first-quarter 2025, including tovecimig to the usual routine of gemcitabine, cisplatin and durvalumab.
Compass Therapeutics, Inc. Worth and Consensus
Compass Therapeutics, Inc. price-consensus-chart | Compass Therapeutics, Inc. Quote
CMPX’s Different Pipeline Packages
Compass Therapeutics’ pipeline contains a number of different clinical-stage developmental candidates.
The corporate is at the moment gearing as much as provoke a part II examine of CTX-471 (CD137 agonist antibody) to deal with sufferers with tumors expressing neural cell adhesion molecule (NCAM or CD56) in mid-2025. CMPX additionally reported that affected person enrollment within the third dosing cohort of an early-stage dose-escalation examine of one other candidate, CTX-8371, has been accomplished. CTX-8371 is a PD-1 x PD-L1 bispecific antibody.
Compass Therapeutics’ novel PD-1 x VEGF-A bispecific antibody, CTX-10726, has undergone intensive preclinical growth over the previous yr. CMPX plans to submit an investigational new drug utility by the tip of the yr, with preliminary proof-of-concept scientific information anticipated in 2026.
Moreover, the corporate estimates its money steadiness to be $127 million as of Dec. 31, 2024, which is anticipated to help operational actions into the primary quarter of 2027.
CMPX’s Zacks Rank & Shares to Take into account
Compass Therapeutics at the moment carries a Zacks Rank #3 (Maintain).
Some better-ranked shares from the sector are Citadel Biosciences CSTL, BioMarin Pharmaceutical BMRN and Alnylam Prescribed drugs ALNY. Whereas CSTL and BMRN at the moment sporta Zacks Rank #1 (Robust Purchase) every, ALNY carries a Zacks Rank #2 (Purchase) at current. You possibly can see the complete list of today’s Zacks #1 Rank stocks here.
Prior to now 30 days, Citadel Biosciences’ earnings estimates for 2024 have elevated from 34 cents to 39 cents per share. Throughout the identical timeframe, the loss per share for 2025 has improved from $1.84 to $1.70. Prior to now three months, shares of Citadel Biosciences have plunged 15.6%.
CSTL’s earnings beat estimates in every of the trailing 4 quarters, delivering a mean shock of 172.72%.
Prior to now 30 days, estimates for BioMarin Pharmaceutical’s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 throughout the identical timeframe. Prior to now three months, BioMarin Pharmaceutical shares have misplaced 4.2%.
BMRN’s earnings beat estimates in every of the trailing 4 quarters, delivering a mean shock of 28.7%.
Prior to now 30 days, estimates for Alnylam Prescribed drugs’ 2024 loss per share have remained fixed at 39 cents. The estimate for 2025 earnings per share is at the moment pegged at 41 cents. Prior to now three months, shares of Alnylam Prescribed drugs have gained 2.3%.
ALNY’s earnings beat estimates in three of the trailing 4 quarters and matched as soon as, delivering a mean shock of 65.67%.
Zacks’ Analysis Chief Names “Inventory Most Prone to Double”
Our workforce of consultants has simply launched the 5 shares with the best likelihood of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This prime choose is among the many most modern monetary corporations. With a fast-growing buyer base (already 50+ million) and a various set of leading edge options, this inventory is poised for giant good points. After all, all our elite picks aren’t winners however this one might far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report
Compass Therapeutics, Inc. (CMPX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
